• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体的分离可变结构域可在凝血因子 VIII 上组装成功能性 Fv 样复合物。

Isolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex.

机构信息

Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

出版信息

Int J Mol Sci. 2022 Jul 23;23(15):8134. doi: 10.3390/ijms23158134.

DOI:10.3390/ijms23158134
PMID:35897712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9330781/
Abstract

Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (V and V) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (FVIII) was shown to inhibit major FVIII functions and is useful in FVIII research. We aimed to investigate the properties of iKM33 enabled with protease-dependent disintegration. Three variants of iKM33 bearing thrombin cleavage sites within the linker were expressed using a baculovirus system and purified by two-step chromatography. All proteins retained strong binding to FVIII by surface plasmon resonance, and upon thrombin cleavage, dissociated into V and V as shown by size-exclusion chromatography. However, in FVIII activity and low-density lipoprotein receptor-related protein 1 binding assays, the thrombin-cleaved iKM33 variants were still inhibitory. In a pull-down assay using an FVIII-affinity sorbent, the isolated V, a mixture of V and V, and intact iKM33 were carried over via FVIII analyzed by electrophoresis. We concluded that the isolated V and V assembled into scFv-like heterodimer on FVIII, and the isolated V alone also bound FVIII. We discuss the potential use of both protease-cleavable scFvs and isolated Fv subunits retaining high affinity to the antigens in various practical applications such as therapeutics, diagnostics, and research.

摘要

单链可变片段 (scFv) 是抗体的抗原识别可变片段,其中两个亚基 (V 和 V) 通过人工接头连接。一种针对凝血因子 VIII (FVIII) 的特定 scFv,即 iKM33,被证明可以抑制 FVIII 的主要功能,在 FVIII 研究中很有用。我们旨在研究具有蛋白酶依赖性解体功能的 iKM33 的特性。使用杆状病毒系统表达了三种在接头内带有凝血酶切割位点的 iKM33 变体,并通过两步色谱法进行纯化。所有蛋白质通过表面等离子体共振保留了对 FVIII 的强结合,并且在凝血酶切割后,如通过尺寸排阻色谱法所示,解离为 V 和 V。然而,在 FVIII 活性和低密度脂蛋白受体相关蛋白 1 结合测定中,凝血酶切割的 iKM33 变体仍然具有抑制作用。在使用 FVIII 亲和吸附剂的下拉测定中,通过电泳分析,分离的 V、V 和 V 的混合物以及完整的 iKM33 通过 FVIII 被携带。我们得出结论,分离的 V 和 V 在 FVIII 上组装成 scFv 样异源二聚体,并且分离的 V 本身也结合 FVIII。我们讨论了在治疗、诊断和研究等各种实际应用中使用既具有蛋白酶可切割性又具有高亲和力的 scFv 和分离的 Fv 亚基的潜在用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/7654c7ea42dc/ijms-23-08134-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/d79a1ad8ed20/ijms-23-08134-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/2a93f2f3fa98/ijms-23-08134-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/81b2b954d024/ijms-23-08134-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/e2d853c15ef3/ijms-23-08134-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/5e759ab3b939/ijms-23-08134-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/446aeabff949/ijms-23-08134-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/97143e28c0e1/ijms-23-08134-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/7654c7ea42dc/ijms-23-08134-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/d79a1ad8ed20/ijms-23-08134-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/2a93f2f3fa98/ijms-23-08134-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/81b2b954d024/ijms-23-08134-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/e2d853c15ef3/ijms-23-08134-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/5e759ab3b939/ijms-23-08134-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/446aeabff949/ijms-23-08134-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/97143e28c0e1/ijms-23-08134-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca2/9330781/7654c7ea42dc/ijms-23-08134-g008.jpg

相似文献

1
Isolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex.抗体的分离可变结构域可在凝血因子 VIII 上组装成功能性 Fv 样复合物。
Int J Mol Sci. 2022 Jul 23;23(15):8134. doi: 10.3390/ijms23158134.
2
Insect cell-based expression and characterization of a single-chain variable antibody fragment directed against blood coagulation factor VIII.基于昆虫细胞的抗凝血因子VIII单链可变抗体片段的表达与特性分析
Protein Expr Purif. 2013 Apr;88(2):201-6. doi: 10.1016/j.pep.2012.12.008. Epub 2013 Jan 7.
3
The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.极低密度脂蛋白受体和低密度脂蛋白受体相关蛋白的结合位点在凝血因子VIII中是共享的。
Blood Coagul Fibrinolysis. 2008 Mar;19(2):166-77. doi: 10.1097/MBC.0b013e3282f5457b.
4
Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain.因子VIII重链的蛋白水解切割是暴露A2结构域内低密度脂蛋白受体相关蛋白结合位点所必需的。
J Thromb Haemost. 2006 Jul;4(7):1487-93. doi: 10.1111/j.1538-7836.2006.01965.x.
5
Expression and characterization of a codon-optimized blood coagulation factor VIII.优化密码子的凝血因子 VIII 的表达和表征。
J Thromb Haemost. 2017 Apr;15(4):709-720. doi: 10.1111/jth.13632. Epub 2017 Feb 21.
6
Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions.单链 Fv 抗体的环化显著抑制了由链间 VH-VL 相互作用介导的特征性聚集。
Molecules. 2019 Jul 18;24(14):2620. doi: 10.3390/molecules24142620.
7
Construction of an scFv library by enzymatic assembly of V(L) and V(H) genes.通过酶促连接 V(L)和 V(H)基因构建 scFv 文库。
J Immunol Methods. 2013 Oct 31;396(1-2):15-22. doi: 10.1016/j.jim.2013.07.003. Epub 2013 Jul 31.
8
A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.一种针对凝血因子VIII的单克隆抗体可抑制血管性血友病因子的结合及凝血酶裂解。
Blood. 1991 May 1;77(9):1929-36.
9
Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.低密度脂蛋白受体相关蛋白与凝血因子IXa在结合凝血因子VIII的A3结构域方面具有共同的结构要求。
J Biol Chem. 2003 Mar 14;278(11):9370-7. doi: 10.1074/jbc.M212053200. Epub 2003 Jan 8.
10
Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.绘制凝血因子 VIII 与低密度脂蛋白受体结合区域的图谱。
J Biol Chem. 2013 Jul 26;288(30):22033-41. doi: 10.1074/jbc.M113.468108. Epub 2013 Jun 10.

引用本文的文献

1
Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.血浆清除凝血因子 VIII 及其半衰期延长在血友病 A 治疗中的应用:当前研究和实践状况的批判性综述。
Int J Mol Sci. 2023 May 11;24(10):8584. doi: 10.3390/ijms24108584.
2
Structure of coagulation factor VIII bound to a patient-derived anti-C1 domain antibody inhibitor.凝血因子 VIII 与患者来源的抗 C1 结构域抗体抑制剂复合物的结构。
Blood. 2023 Jul 13;142(2):197-201. doi: 10.1182/blood.2023020181.

本文引用的文献

1
Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors.纳米抗体修饰的 AAV2 基因治疗载体可提高对人 CD4+T 细胞的靶向性。
PLoS One. 2021 Dec 20;16(12):e0261269. doi: 10.1371/journal.pone.0261269. eCollection 2021.
2
A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies.一种用于递送小型抗体的病毒:基于腺相关病毒递送纳米抗体的新型靶向疗法。
Microorganisms. 2021 Sep 15;9(9):1956. doi: 10.3390/microorganisms9091956.
3
Systematic Engineering of Optimized Autonomous Heavy-Chain Variable Domains.
优化自主重链可变结构域的系统工程。
J Mol Biol. 2021 Oct 15;433(21):167241. doi: 10.1016/j.jmb.2021.167241. Epub 2021 Sep 9.
4
Molecular chaperone RAP interacts with LRP1 in a dynamic bivalent mode and enhances folding of ligand-binding regions of other LDLR family receptors.分子伴侣 RAP 以动态二价模式与 LRP1 相互作用,并增强其他 LDLR 家族受体配体结合区域的折叠。
J Biol Chem. 2021 Jul;297(1):100842. doi: 10.1016/j.jbc.2021.100842. Epub 2021 May 29.
5
Nanobody: a promising toolkit for molecular imaging and disease therapy.纳米抗体:用于分子成像和疾病治疗的一种有前景的工具集。
EJNMMI Res. 2021 Jan 19;11(1):6. doi: 10.1186/s13550-021-00750-5.
6
Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications.骆驼科动物来源的单链抗体在止血中的作用:作用机制、诊断及治疗应用
Res Pract Thromb Haemost. 2020 Sep 9;4(7):1087-1110. doi: 10.1002/rth2.12420. eCollection 2020 Oct.
7
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.BIVV001 融合蛋白作为血友病 A 的凝血因子 VIII 替代疗法。
N Engl J Med. 2020 Sep 10;383(11):1018-1027. doi: 10.1056/NEJMoa2002699.
8
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.凝血酶,神经血管界面处凝血、炎症和神经毒性的介质:对阿尔茨海默病的影响。
Front Neurosci. 2020 Jul 24;14:762. doi: 10.3389/fnins.2020.00762. eCollection 2020.
9
Protease-activated prodrugs: strategies, challenges, and future directions.蛋白酶激活前药:策略、挑战与未来方向。
FEBS J. 2020 May;287(10):1936-1969. doi: 10.1111/febs.15227. Epub 2020 Feb 26.
10
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A.延长半衰期的因子 VIII 产品在血友病 A 中的获益和局限性。
Expert Opin Investig Drugs. 2020 Mar;29(3):303-309. doi: 10.1080/13543784.2020.1723547. Epub 2020 Jan 31.